Topical treatment for macular edema in retinitis pigmentosa

Poster Details

First Author: V.Poposki SPAIN

Co Author(s):    A. Martinez Palmer   C. Pueyo   D. Poposka   D. Vilaplana                    

Abstract Details


Retinitis pigmentosa (RP) is a set of inherited diseases and an important cause of blindness. The most frequent symptoms are nocturnal blindness and reduced visual field. Two complications affecting early central vision are cataract and cystoid macular edema (CME). The CME in RP is due to an involvement of the blood-retinal barrier. Carbonic anhydrase inhibitors (CAI) act on the pigment epithelium of the retina, favoring the pumping of fluid and increasing adhesion.


Hospital de la Esperanza, Park de Salut Mar


A 44-year-old patient, with previously diagnosed RP and periodically monitored, came to the clinic for gradual visual loss in her left eye (LE). In the anterior segment a bilateral correct pseudophakia was found. Funduscopically, the classic clinical triad of RP and macular edema was observed in the LE. Intraretinal cysts were confirmed tomographically, with loss of foveal depression. Dorzolamide eyedrops were prescribed for 3 months.


At the control visits, both functional and anatomical improvements were observed, and there was no relapse within 3 months of follow-up (without any treatment). Topical administration of CAI was well tolerated and avoids oral side effects such as paresthesia in the extremities, fatigue, appetite lost, kidney stones, or severe anaemia.


This particular case allows us to consider topical treatment as a first choice therapy in patients with macular edema due to RP, because it obtains a positive, lasting response, and without side effects.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy